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Summary
 
The current knowledge of CD4 function is limited to its role as a necessary coreceptor in
TCR-initiated signaling. We have investigated whether CD4 regulates additional T cell func-
tions. Using human primary resting CD4
 
1
 
 T cells, we demonstrate that CD4 activation is suf-
ficient to induce lymphocyte death. Immediately after CD4 cross-linking, CD4
 
1
 
 T cells are
rendered susceptible to apoptosis mediated by TNF or FasL. This, together with the concomi-
tant induction of FasL within the same population, results in significant CD4
 
1
 
 T cell death in
vitro. The CD4-dependent induction of susceptibility to apoptosis that is mediated by TNF or
FasL is protein synthesis independent but phosphorylation dependent. After CD4 activation,
PKC regulates susceptibility to apoptosis mediated by FasL but not the induction of susceptibil-
ity to TNF-dependent apoptosis. Moreover, significant differences between CD3 and CD4 ac-
tivation were observed with regards to the kinetics of induction of CD4
 
1
 
 T cell susceptibility
to FasL- and TNF-mediated apoptosis. Altogether, these results provide a model with which to
study the molecular mechanisms regulating lymphocyte survival after CD4 activation, and
highlight the potential role of CD4 in controlling lymphocyte apoptosis under physiological
conditions or in disease states such as HIV infection.
 
T
 
he functional relevance of CD4 in the physiology of
CD4
 
1
 
 T lymphocytes is partially understood. In the
context of antigen presentation, CD4 is required to en-
hance the activation and proliferation that ensues after
TCR engagement. An additional function of CD4 may be
to control the fate of lymphocyte survival after the initial
immune response. Interruption of the CD4–MHC class II
interactions that occurs during antigen presentation inhibits
the CD4
 
1
 
 T cell apoptosis triggered by subsequent reen-
gagement of the TCR (1). This complementary function
of CD4 may be of relevance not only to controlling the
physiological immune response, but in disease states in
which CD4 may become activated independently from
TCR coactivation such as in the context of HIV infection.
Accumulating data suggest that depletion of CD4
 
1
 
 T
cells in HIV-infected individuals is in part secondary to en-
hanced lymphocyte apoptosis due to an HIV-dependent
dysregulation of the physiological mechanisms that control
peripheral T cell homeostasis. The interaction between Fas
and TNFRI with the corresponding ligands, Fas ligand
(FasL)
 
1
 
 and TNF, controls the T cell expansion after an im-
mune response (2–4). In HIV-infected individuals, a large
portion of peripheral, and presumably uninfected, CD4
 
1
 
 T
cells are found to be highly susceptible to FasL-mediated
apoptosis (5, 6), suggesting that FasL–Fas interactions may
play a role in CD4
 
1
 
 T cell depletion. How HIV infection
directly or indirectly leads to an enhanced state of suscepti-
bility to FasL-dependent apoptosis is currently unknown. 
One potential mechanism leading to enhanced suscepti-
bility to apoptosis includes the interaction of HIV glyco-
protein (gp)120 with CD4. In vitro, CD4 activation of resting
human CD4
 
1
 
 T cells by anti-CD4 antibodies or HIV gp120
is necessary in order for a second signal, such as TCR stim-
ulation, to induce apoptosis (7, 8). Moreover, in in vivo
murine models, activation of CD4 causes a significant
CD4
 
1
 
 T lymphopenia secondary to an increased rate of
cell apoptosis in lpr
 
1
 
/
 
1
 
 but not in lpr
 
2
 
/
 
2
 
 mice (9, 10). Al-
though these observations suggest that CD4 activation con-
fers a “negative” signal that primes the lymphocyte to apop-
tosis presumably mediated by Fas–FasL interactions, several
questions remain unresolved. Namely, whether CD4 acti-
vation alone is sufficient to confer susceptibility to apoptosis-
inducing ligands, such as FasL or other ligands, and if so,
what is the molecular mechanism(s) whereby CD4 activa-
tion leads a resting, and therefore apoptosis-resistant, T
 
1
 
Abbreviations used in this paper:
 
 FasL, Fas ligand; GF, PKC inhibitor
GF109203X; gp, glycoprotein; PKC, protein kinase C; XL, cross-linking.
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lymphocyte into a state of susceptibility to apoptosis. Previ-
ous in vitro studies have suggested that combination of spe-
cific cytokines, such as TNF and IFN-
 
g
 
, that are secreted
by PBLs after their activation by CD4 are sufficient to ren-
der the CD4
 
1
 
 T cell subpopulation susceptible to apoptosis
(11). Although this suggests that indirect, CD4-dependent
mechanisms regulate susceptibility, it is also possible that
signal transduction pathways that are activated by CD4
cross-linking may directly lead to a state of susceptibility.
This could be achieved by targeting molecules that control
susceptibility to cell death pathways triggered by Fas or
TNFR, among other receptors.
In this report, we have investigated whether CD4 con-
fers susceptibility to cell death in primary CD4
 
1
 
 T cells,
and the molecular mechanisms involved in this. Our results
indicate that CD4 activation induces a net state of suscepti-
bility to apoptosis that can be mediated not only by FasL
but also by TNF. The induction of such a state of suscepti-
bility is protein synthesis–independent, suggesting that it is
mediated directly by the CD4-initiated signal transduction
pathway. Moreover, we have identified protein kinase C
(PKC) as a target of the CD4-initiated signal transduction
pathway that is required for the induction of susceptibility
to FasL-mediated apoptosis. Altogether, these studies dem-
onstrate the importance of CD4 in regulating T cell sur-
vival, and its potential relevance in the control of CD4
 
1
 
 T
cell homeostasis after an immune response and in the in-
duction of CD4
 
1
 
 T cell depletion after HIV infection.
 
Materials and Methods
 
Cells and Culture Conditions.
 
To isolate CD4
 
1
 
 T cells, PB-
MCs from healthy donors were isolated from buffy coats by den-
sity gradient centrifugation (Ficoll-Hypaque; Pharmacia Biotech,
Piscataway, NJ). The resulting PBMCs were depleted of mono-
cytes by two cycles of plastic adherence, and CD3
 
1
 
 T cells were
purified by neuraminidase-treated SRBC rosetting. CD3
 
1
 
 T cells
were depleted of CD8
 
1
 
 T cells by negative selection using anti-
CD8 antibodies (Caltag Labs., South San Francisco, CA) fol-
lowed by goat anti–mouse IgG magnetic beads (Dynal, Lake Suc-
cess, NY). The remaining cell population was repeatedly found
to be 100% CD3
 
1
 
 T cells and 
 
>
 
98% CD4
 
1
 
 T cells as determined
by flow cytometry in each experiment. CD4
 
1
 
 T cells used in the
various experiments were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA),
2 mM l-glutamine, and antibiotics (penicillin: 100 U/ml; strepto-
mycin: 100 
 
m
 
g/ml; Whittaker Bioproducts, Walkersville, MD) at
2 
 
3
 
 10
 
6
 
 cells/ml.
 
Antibodies and Reagents.
 
F(ab
 
9
 
)
 
2
 
 fragments of the anti-Fas
monoclonal antibodies M3 and M33, and fusion proteins con-
taining the Fc portion of mouse IgG1 and the extracellular do-
main of Fas (FasFc), TNFRI (TNFRFc), and CD30 (CD30Fc)
have been previously described (12–14). The apoptosis-inducing
anti-Fas cross-linking monoclonal antibodies (clone CH-11;
IgM) was purchased from Upstate Biotechnology (Lake Placid,
NY). Human recombinant TNF was purchased from Genzyme
(Cambridge, MA). The anti–human FasL monoclonal antibody
NOK1 conjugated with PE was provided by Dr. Hideo Yagita
(Yuntendo University, Japan) (15). The PKC inhibitor GF109203X
(GF) was purchased from Calbiochem (San Diego, CA). The
protein synthesis inhibitor cycloheximide was purchased from
Sigma Chemical Co. (St. Louis, MO).
 
CD4
 
1
 
 T Cell Cross-linking.
 
CD4
 
1
 
 T cells were incubated
with the anti-CD4 antibody Leu-3a (Becton Dickinson, San Jose,
CA), anti-CD3 (OKT3; American Type Culture Collection,
Rockville, MD), or an isotype-matched control (mouse IgG1;
Becton Dickinson) at a concentration of 5 
 
m
 
g/2 
 
3
 
 10
 
6
 
 cells/ml
for 1 h at 4
 
8
 
C. Recombinant HIV gp120 (Protein Sciences
Corp., Meriden, CT) was added at a concentration of 5 
 
m
 
g/2 
 
3
 
10
 
6
 
 of CD4
 
1
 
 T of cells /ml for 1 h at 4
 
8
 
C. Anti-CD4 antibody or
gp120-bound cells were then washed and transferred to 24-well
Nunclon
 
Ò
 
 plates (Sigma Chemical Co.) that had been previously
coated with goat anti–mouse (GAM; Biosource, Camarillo, CA)
or anti-gp120 antiserum (AIDS Research and References Re-
agent Program, National Institutes of Health, Bethesda, MD) (16,
17), and incubated for 1 h at 37
 
8
 
C. Secondary antibody precoat-
ing was performed using 20 
 
m
 
g of GAM in 200 
 
m
 
l, or using 20 
 
m
 
l
of anti-gp120 serum in 200 
 
m
 
l of 0.05 M carbonate buffer/well
for 2 h at 37
 
8
 
C and washed twice with 10% RPMI 1640. After
the hour of CD4 cross-linking, CD4
 
1
 
 T cells were harvested by
gentle pipetting, washed, counted, and transferred to 24-well
plates at a concentration of 2 
 
3
 
 10
 
6
 
 cells/ml/well or to 96-well
plates at a concentration of 10
 
5
 
 cells/ml/well. Each point was
processed in triplicate.
 
Cell Death Induction and Analysis.
 
To determine Fas- or TNF-
mediated apoptosis, CD4 cross-linked cells were treated with
anti-Fas cross-linking IgM antibody (CH-11) or TNF for the dif-
ferent incubation times. Percentage of cell mortality was calcu-
lated using trypan blue dye exclusion as follows: (total number of
blue cells) / (100 
 
3
 
 total number of cells). Results from cultures
from triplicate cells were used to calculate the mean and standard
deviation.
Flow cytometry analysis of cell apoptosis was performed as
previously described (18). In brief, cells are harvested, washed,
and resuspended in 1 ml of PBS. 1 
 
m
 
g/ml of Hoeschst 33342
(Calbiochem, Corp.) was added and incubated for 10 min on ice.
Cells were then washed and resuspended at 10
 
6
 
 cells/ml of PBS
with 2 
 
m
 
g/ml of propidium iodide (Sigma Chemical Co.). Cells
were kept on ice and analyzed immediately on a FACStar
 
Plus
 
Ò
 
flow cytometer and the results were calculated using CellQuest
 
Ò
 
software (Becton Dickinson). Percentage of specific apoptosis was
calculated as: 100 
 
3
 
 (percentage of apoptosis of CD4–cross-linked or
IgG1 CD4
 
1
 
 T cells 
 
2
 
 percentage of apoptosis present in un-
treated [noncross-linked] CD4
 
1
 
 T cells [spontaneous apoptosis]/
[100 
 
2
 
 percentage of spontaneous apoptosis]).
 
Flow Cytometry Analysis of FasL.
 
Flow cytometry for surface
staining was performed on 10
 
6
 
 CD4
 
1
 
 T cells. Cells were washed
with PBS followed by a 20-min incubation at 4
 
8
 
C with 1 
 
m
 
g of
FasL (NOK1)-PE (15) or mouse IgG1 PE isotype. Cells were
then washed and fixed in 1% paraformaldehyde. Flow cytometry
was performed in FACScan
 
Ò
 
 and analysis was done using
CellQuest
 
Ò
 
 software.
 
Results
 
CD4 Activation Is Sufficient to Induce Cell Death by Apopto-
sis of Purified CD4
 
1
 
 T Cells.
 
Previous reports demonstrated
that CD4 activation primes CD4
 
1
 
 T cells for the induction
of T cell apoptosis triggered by a second signal provided by
accessory cells or activation via the TCR (7, 8, 10, 11). To
determine if CD4 activation confers susceptibility to apop-
tosis-inducing ligands such as FasL and TNF, preliminary 
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experiments were performed using purified CD4
 
1
 
 T cells
that had been CD4 cross-linked for different time periods
in order to identify the optimal culture conditions. Surpris-
ingly, in these preliminary experiments a significant mortal-
ity of the purified CD4
 
1
 
 T cell population that had under-
gone CD4 cross-linking (XL) was observed as early as at 18 h
as compared to minimum cell mortality present in the control
cultures treated with IgG isotype and secondary antibodies
(IgG cross-linked) during the same time points (Fig. 1 
 
A
 
).
To confirm these observations and exclude any nonspecific
toxicity of anti-CD4 antibodies, we tested whether alterna-
tive modes of CD4 activation, such as that achieved by
HIV gp120, would also result in the rapid induction of
CD4
 
1
 
 T cell death. Purified resting CD4
 
1
 
 T cells were in-
cubated with gp120 followed by cross-linking of anti-
gp120 antibodies, and cell viability was analyzed at different
time points thereafter. As shown in Fig. 1 
 
B
 
, significant cell
death was observed 18 h after CD4 activation by gp120XL,
as compared to that present in untreated, anti-gp120 anti-
body-treated or gp120-treated CD4
 
1
 
 T cell cultures, thus
confirming the specificity of CD4 activation-mediated cell
death. To further investigate whether the decrease in cell
viability induced by CD4XL was mediated by apoptosis,
flow cytometric techniques were used, which demon-
strated a significant degree of apoptosis at 18 h after
CD4XL but not IgGXL (Fig. 1 
 
C
 
). Altogether, these re-
sults indicated that CD4 activation was sufficient to trigger
CD4
 
1
 
 T cell apoptosis in the absence of accessory cells or
TCR engagement in a monocyte-depleted, 
 
>
 
98% pure
primary CD4
 
1
 
 T cells.
 
CD4XL Mediates Apoptosis through Fas–FasL Interactions and
Induces Susceptibility to TNF-mediated Apoptosis.
 
To identify
the mechanisms whereby CD4 activation directly leads to
T cell apoptosis, we investigated the role of two separate
apoptosis-inducing ligands and their corresponding recep-
tors that had been previously shown to participate in T cell
apoptosis (FasL and Fas and TNF and TNFR; 2–4). Puri-
fied CD4
 
1
 
 T cells were either CD4 cross-linked or IgG1-
treated and were immediately cultured in the presence of
either a Fas fusion protein (FasFc), a TNFRI fusion protein
(TNFRFc), or a control fusion protein (CD30Fc). As
shown in Fig. 2 
 
A
 
, FasFc but not TNFRFc or CD30Fc fu-
sion proteins prevented CD4XL-induced T cell apoptosis,
supporting the role of FasL–Fas interactions in CD4-medi-
ated T cell death. This was further confirmed in additional
experiments in which anti-Fas blocking (M3) or nonblock-
ing antibodies (M33) were added immediately after
CD4XL or IgG1XL. As shown in Fig. 2 
 
B
 
, M3 but not
M33 interfered with the CD4XL-induced death of pure
CD4
 
1
 
 T cells.
The above results suggest that CD4 activation of resting
CD4
 
1
 
 T cells either induces a de novo state of susceptibil-
ity to FasL-mediated apoptosis (assuming a constitutive
Figure 1. CD4 activation is
sufficient to induce apoptosis of
CD41 T cells. (A) CD4XL or
IgG1XL purified CD41 T cells
were washed, harvested, counted,
and transferred to separate wells.
Cell mortality was analyzed at 18 h
after cross-linking as determined
by trypan blue dye exclusion. (B)
Pure CD41 T cells were incu-
bated with HIV gp120IIIB for 1 h
and then transferred to anti-
gp120–coated plates and pro-
cessed and analyzed as in A. (C)
CD41 T cells were CD4 cross-linked or IgG cross-linked as in A, and the percentage of apoptosis was analyzed by flow cytometry in Hoeschst and pro-
pidium iodide–stained cells as described in Materials and Methods. The data in A and B represents the mean and the corresponding standard deviations of
triplicate points within each experiment.
Figure 2. CD4XL mediates ap-
optosis through FasL–Fas interac-
tion. (A) Pure CD41 T cells were
CD4 cross-linked or IgG1 cross-
linked in the presence of FasFc,
TNFRFc, CD30Fc (each at 30
mg/ml). After 1 h of cross-link-
ing, cells were processed as in
Fig. 1 A and cell death was ana-
lyzed 18 h later. (B) IgG1XL or
CD4XL of CD41 T cells was
performed either in the presence
or absence of F(ab9)2 fragments
of blocking (M3) or nonblocking
(M33) anti-Fas antibodies used at
30 mg/ml for 18 h. Cell death
was calculated as in Fig. 1 A. The
data represents the mean and stan-
dard deviation of triplicate points
within each experiment.714 CD4 Regulates Susceptibility to Fas and TNF
presence of FasL in their surface) and/or that it triggers de
novo expression of FasL. To dissect these two mechanisms,
we focused first on determining whether CD4 activation
induces a state of susceptibility to FasL-dependent apopto-
sis. CD41 T cells were either CD4 cross-linked or IgG1
cross-linked for 1 h followed by the addition of anti-Fas
cross-linking antibodies. As shown in Fig. 3 A, addition of
anti-Fas cross-linking antibodies further increased the level
of CD4XL-induced apoptosis, which, as shown in Fig. 2, is
mediated by Fas–FasL interactions, suggesting that CD4–
cross-linked cells are susceptible to FasL-mediated apoptosis.
We next investigated whether FasL expression is consti-
tutive within the purified CD41 T cell population or in-
duced after CD4XL. CD41 T cells were CD4 cross-linked
or IgG1 cross-linked, and stained with PE-conjugated anti-
FasL antibodies at different time points. FasL expression
was analyzed 1, 2, and 6 h after CD4 activation. As shown
in Fig. 3 B, FasL is detected in the surface of CD41 T cells
as early as 1 h after CD4XL. FasL expression was found to
be rapidly induced, and in a transient fashion, since it could
not be detected by 6 h after CD4 activation. From these
results it is inferred that CD4 activation has a dual function
that ultimately results in CD41 T cell death within a ho-
mogeneous population. CD4 activation confers susceptibil-
ity to FasL-mediated apoptosis and induces de novo ex-
pression of FasL within the same CD41 T cell culture.
In view of the fact that Fas and TNFRI share common
intracytoplasmic proteins of the signal transduction path-
Figure 3. CD4XL induces susceptibility to FasL- and TNF-mediated
apoptosis and FasL expression. (A) CD41 T cells were CD4 cross-linked
or IgG1 cross-linked and incubated with anti-Fas cross-linking antibody
(CH-11; 250 ng/ml) for 18 h. (B) Membrane-associated FasL was mea-
sured 1 h after CD4XL or IgGXL, using isotype (dashed line) or anti-FasL
(NOK-1)PE-conjugated antibodies (bold line). The mean channel fluores-
cence (DMCF) was calculated for each treatment point by subtracting the
MCF for the isotype-stained sample from that of the FasL-stained sample.
(C) CD4XL or IgG1XL was performed as in Fig. 1 A in the presence of
M3 F(ab9)2 for 1 h, after which TNF (100 ng/ml) was added for 18 h and
cell death was analyzed as in Fig. 1 A. The data represents the mean and
standard deviation of triplicate points within each experiment.
Figure 4. Induction of susceptibility to FasL- and TNF-mediated apop-
tosis is protein synthesis independent. CD41 T cells were treated with
CHX (10 mg/ml) for 30 min before CD4XL or IgG1XL. After 1 h of
cross-linking, CD41 T cells were transferred to separate wells and incu-
bated either with anti-Fas crosslinking antibodies (CH-11, at a concentra-
tion of 250 ng/ml) or human recombinant TNF (100 ng/ml) for 18 h.
The data represents the mean and standard deviation of triplicate points
within each experiment.715 Algeciras et al.
ways that lead to cell death by apoptosis (19, 20), we next
tested whether CD4XL induced susceptibility not only to
FasL-mediated apoptosis but also to TNF. To dissect the
effect of FasL–Fas interactions from the possible induction
of susceptibility to TNF-mediated apoptosis, CD41 T cells
that had undergone CD4XL or IgG1XL were incubated
with anti-Fas blocking antibodies (M3) in the presence of
TNF. As shown in Fig. 3 C, a significant degree of TNF-
induced apoptosis was observed in CD4–cross-linked but
not in IgG1–cross-linked T cells once FasL–Fas interactions
are blocked by M3. Altogether, these results indicate that
CD4 activation triggers the susceptibility to both TNF and
FasL-mediated apoptosis, but that only FasL is produced after
CD4 activation of a homogenous CD41 T cell population.
Induction of Susceptibility to FasL- and TNF-mediated Apop-
tosis Is Protein Synthesis–independent. To identify potential
mechanisms that could explain the induction of susceptibil-
ity to apoptosis triggered by CD4 activation, we tested
whether the induction of a susceptibility state to FasL- and
TNF-mediated apoptosis after CD4 activation requires
new protein synthesis. For this, cells were either IgG1
cross-linked or CD4 cross-linked in the presence of cyclo-
heximide, followed by treatment with either anti-Fas cross-
linking antibodies or TNF. The presence of cycloheximide
caused a significant reduction in the CD4XL-induced cell
death of purified CD41 T cells (Fig. 4, compare lanes 7 and
10), suggesting that either the induction of susceptibility
and/or the production of FasL is protein synthesis–depen-
dent. To dissect these two possible mechanisms, cyclohex-
imide-treated CD41 T cells were CD4 cross-linked and in-
cubated in the presence of either anti-FasXL antibodies or
TNF. Results from these experiments demonstrate a signif-
icant degree of cell death mediated by either of these two
ligands (Fig. 4, lanes 11 and 12). These observations indi-
cate that the induction of a state of susceptibility to FasL- or
TNF-dependent apoptosis is protein synthesis–independent,
whereas the production of FasL after CD4 activation is
protein synthesis–dependent. Moreover, it strengthens the
observation that direct mechanisms rather than indirect
ones such as those mediated by the production of cytokines
participate in the induction of susceptibility to apoptosis.
PKC Mediates Susceptibility to FasL-dependent Cell Death
after CD4 Activation. To further investigate the mecha-
nisms mediating susceptibility to FasL and TNF-dependent
apoptosis after CD4 activation, we focused on protein syn-
thesis–independent processes such as post-translational
modifications of second messengers of the CD4-initiated
signal transduction pathway. Although this pathway is poorly
understood in primary human T cells, in transformed T
cells lines, tyrosine kinases such as p56lck (21, 22), increased
intracellular [Ca21] and inositol 3,4,5-phosphate (23), p21
ras (24), and the translocation of the conventional isoforms
of PKC from the cytosol to membrane (25–28) have been
identified as key members of the CD4-initiated signal trans-
duction pathway. We first analyzed if PKC is involved in me-
diating susceptibility to FasL-mediated cell death after CD4
activation by using GF109203X (GF). CD41 T cells were
pretreated with GF, followed by CD4XL or IgGXL, and
were incubated in the presence of anti-Fas cross-linking an-
tibodies. GF completely blocked the cell death observed after
CD4XL (Fig. 5 A). Moreover, addition of anti-Fas cross-
linking antibodies in the presence of GF did not induce death
of CD4–cross-linked cells, suggesting that conventional PKC
isoforms are involved in controlling susceptibility to FasL-
mediated apoptosis in primary, CD4 activated CD41 T cells.
This result indicates that induction of susceptibility to FasL-
mediated apoptosis requires PKC-dependent pathways.
We next tested whether induction of susceptibility to
TNF-mediated apoptosis triggered by CD4 activation (as
shown in Fig. 3 C) requires a PKC-dependent signaling
pathway. For this, CD41 T cells were pretreated with GF
and CD4XL in the presence of M3 (to prevent cell death
induced by Fas–FasL interactions). TNF induced a 30%
rate of CD41 T cell death that was not reversed by pre-
treatment with GF (Fig. 5 B), suggesting that susceptibility
to FasL- and TNF-mediated apoptosis following CD4XL is
regulated by PKC-dependent and PKC-independent path-
ways, respectively.
To further confirm the effect of PKC in mediating sus-
ceptibility to Fas-induced cell death, we tested whether di-
rect activation of PKC can mimic the effect of CD4 activa-
tion by using a PKC activator such as PMA. CD41 T cells
were treated with PMA for 1 h in the presence or absence
Figure 5. Inhibition of PKC
reverts CD4XL-induced suscep-
tibility to FasL- but not TNF-
mediated apoptosis. (A) Pure
CD41 T cells were pretreated
with 3 mM of GF for 1 h. Cells
were then CD4 cross-linked or
IgG1 cross-linked for 1 h and
transferred to separate wells.
Thereafter, anti-Fas cross-linking
antibody (CH-11, at 250 ng/ml)
was added for an additional 18 h.
(B) CD41 T cells were pre-
treated with GF as in A. Cells
were CD4 cross-linked or IgG
cross-linked in the presence of
F(ab9)2 fragments of anti-Fas M3
antibodies. After 1 h of cross-
linking, TNF (100 ng/ml) was added and incubated for an additional 18 h.
(C) CD41 T cells were pretreated or not with 3 mM GF for 1 h before
PMA stimulation. Cells were then stimulated with PMA (250 ng/ml) for
1 h in the presence or absence of F(ab9)2 fragments of anti-Fas antibodies
M3 or M33. Cells were washed, transferred to separate wells, and incu-
bated for 18 h with anti-Fas cross-linking antibodies CH-11 (250 ng/ml)
or TNF (100 ng/ml).716 CD4 Regulates Susceptibility to Fas and TNF
of GF, and then incubated in the presence of anti-Fas
cross-linking antibodies or TNF. As shown in Fig. 5 C,
PMA alone induced a moderate degree of cell death, which
was reversed by M3 (compare lanes 4 and 5), suggesting
that PMA-induced CD41 T cell death is mediated by
FasL–Fas interactions. The reversal of the moderate degree
of PMA-induced CD41 T cell death was also blocked by
GF (Fig. 5 C, lane 9), indicating that PMA induces a state
of susceptibility to FasL dependent apoptosis via PKC-
dependent pathways. This was further confirmed by the
addition of anti-Fas cross-linking antibodies to PMA-
treated cells, which further enhanced CD41 T cell apopto-
sis in a GF-sensitive fashion (Fig. 5 C, lanes 7 and 10). In-
terestingly, TNF-mediated apoptosis was not observed in
PMA-treated CD41 T cells (lane 8), further strengthening
the proof that susceptibility to TNF-mediated apoptosis of
CD4-activated T cells is PKC-independent.
These results suggest that susceptibility to FasL and
TNF-mediated cell death in primary CD4 T cells is regu-
lated by at least two different pathways; PKC-dependent in
the Fas signaling pathways, and PKC-independent in the
TNFR signaling pathway. Both of these paths appear to be
separately targeted after CD4 activation.
CD4 and CD3 Activation Shows Different Kinetics for Induc-
tion of Susceptibility to Fas-mediated Apoptosis. T cell activa-
tion via the T cell receptor results in the activation of vari-
ous PKC isoforms (28–30). Since direct activation of PKC
through PMA is sufficient to induce susceptibility to Fas-
mediated cell death, we asked whether CD3 activation re-
sults in susceptibility to FasL and/or TNF-mediated cell
death. To compare cell death induced by CD3XL and
CD4XL, cells were stimulated with anti-CD4, anti-CD3
or IgG1 for 1 h and cell viability in the absence or in the
presence of an 18-h incubation with anti-Fas antibodies
was analyzed at 24 and 72 h. CD4XL of resting pure CD41
T cells induces significant cell death by 24 h, whereas
CD3XL did not lead directly to cell death at this early time
point (Fig. 6, lane 7) despite the increase in the expression
of the activation marker CD69 (data not shown). More-
over, CD3XL CD41 T cells were not found to be suscep-
tible to anti-Fas antibodies added immediately after
CD3XL (Fig. 6, lane 9). However, addition of anti-Fas an-
tibodies 48 h after CD3XL resulted in a 30% cell mortality
of the CD41 T cells (Fig. 6, lane 10) In contrast to CD4
activation, CD3 activation of CD41 T cells did not lead to
susceptibility to TNF-mediated apoptosis at either the 24
or 72 h time points (Fig. 6, lanes 11 and 12). These results
suggest the use of different signal transduction pathways for
the induction of susceptibility to FasL and TNF-mediated
apoptosis after CD4 and CD3 activation.
Discussion
This report demonstrates that CD4 activation of resting
T cells leads directly to an aberrant state of susceptibility to
apoptosis mediated by either FasL or TNF. Moreover, the
simultaneous induction of FasL after CD4 activation ex-
plains the in vitro death by apoptosis of purified CD41 T
cells. The fact that protein synthesis is not required to trig-
ger the state of susceptibility to apoptosis that ensues after
CD4 activation argues for direct posttranslational modifica-
tions of second messengers of the Fas- or TNFR-depen-
dent pathways. This argument is further supported by the
fact that inhibition of PKC or tyrosine kinases reverse the
CD4-mediated induction of susceptibility to FasL- but not
to TNF-induced apoptosis. In addition, this study high-
lights potential differences in the control of lymphocyte
survival by CD3- and CD4-initiated signal transduction
pathways. Altogether, these observations require that the
function of CD4 should be revisited and expanded to ad-
dress its role as a key receptor in CD41 T cell homeostasis
as it relates to the immune response and HIV-induced im-
munopathogenesis.
Our observation that CD4 activation leads to a state of
susceptibility to FasL-dependent apoptosis extends previous
observations. CD4 activation had been shown to prime the
CD41 T cell to apoptosis if a second signal such as TCR
engagement or the presence of accessory cells was provided
(7, 8, 11). It is now known that such “second” signals in-
duce the expression of FasL, as is the case for TCR activa-
tion (31–33) or constitutively express FasL, as in the case of
antigen-presenting cells (14, 34). In addition, our study
supports previous observations using lpr1/1 mice for which
it was demonstrated that CD4 activation in vivo did not re-
sult in CD41 T cell depletion and apoptosis as was ob-
served in lpr2/2 mice (9, 10). What was more surprising
was the observation that CD4 activation could lead to the
Figure 6. CD4XL and CD3XL show different kinetics for induction of
susceptibility to Fas-mediated apoptosis. CD41 T cells were CD4 cross-
linked,  CD3 cross-linked, or IgG1 cross-linked. After 1 h of XL, CD41 T
cells were transferred to separate wells and incubated either with anti-FasXL
antibodies (CH-11, at a concentration of 250 ng/ml) or human recombinant
TNF (100 ng/ml) for 24 h or incubated for 72 h followed by the addition of
anti-Fas or TNF as above for an additional 18 h. The data represents the
mean and standard deviation of triplicate points within each experiment.717 Algeciras et al.
susceptibility of apoptosis triggered by TNF. The function
of TNF as a key ligand in regulating peripheral T lympho-
cyte homeostasis is becoming more apparent (4, 6), and
therefore our results may explain how CD41 T cells may
become susceptible to TNF. This may be relevant not only
to the physiological control of lymphocyte survival after
antigen presentation, but also to HIV pathogenesis (see be-
low). Future studies should address whether CD4 activa-
tion leads also to a susceptibility state to additional apopto-
sis-inducing receptors/ligands, some of which may share
common signal transduction pathways to those down-
stream of Fas or TNFRI.
Interfering with Fas–FasL interactions resulted in a
nearly complete reversal of CD41 T cell apoptosis after
CD4 activation in in vitro cultures of purified CD41 T
cells. This implies that although CD4 triggers a significant
degree of susceptibility to several apoptosis-inducing
ligands, it appears to only induce the production of FasL,
thus explaining the observed degree of cell death by apop-
tosis. Previous studies have demonstrated that CD4 activa-
tion of PBL or monocytes induces the transcription (35)
and, recently, the expression of FasL (6, 36). The fact that
cycloheximide blocked the CD4 mediated apoptosis by
Fas–FasL interactions without interfering with the state of
susceptibility supports the de novo production of FasL,
which presumably occurs through transcriptional mecha-
nisms triggered by a CD4-initiated signal transduction
pathway. Therefore, the combination of the induction of
susceptibility to FasL or TNF and the production of FasL
by CD4 activation within primary CD41 T cells supports
the key role that CD4 may play in mediating death of this
important immune cell.
When CD4 and CD3 activation were separately com-
pared in this study, it was observed that CD3 activation
alone did not directly induce cell death at earlier (24 h) or
later (72 h) time points, despite the observation of CD3-
mediated cell proliferation and expression of CD69. This,
together with the fact that CD3 activation induced suscep-
tibility to FasL- but not TNF-dependent apoptosis at 72 h,
argues toward different signaling pathways initiated by these
two lymphocyte receptors in controlling T cell survival.
The role of CD4 in the context of antigen presentation of
resting naive peripheral CD41 T cells warrants further
study. Although our study did not focus on the interaction
between CD4- and TCR/CD3-initiated signal transduc-
tion pathways to understand how CD4 may modify lym-
phocyte survival in this context, a previous study showed
that TCR engagement blocks the CD41 T cell apoptosis
observed in in vivo murine models after the administration
of anti-CD4 antibody (37). In fact, coactivation of CD3
and CD4 resulted in the reversal of CD4-triggered cell
death (Algeciras, A., and C.V. Paya, unpublished observa-
tions). It will be of interest to explore whether coactivation
of TCR/CD3 and CD4 modifies FasL expression or the
CD4-initiated state of susceptibility to FasL- and TNF-
mediated apoptosis. Likewise, it is theoretically possible that
other coactivation receptors/ligands such as CD28/B7 may
also interfere with the CD4 initiated susceptibility to apop-
tosis by increasing the level of antiapoptotic molecules such
as shown for the case of bclxL after CD28 activation (38).
In addition to the potential key role of CD4 in control-
ling the immune response that occurs after antigen presen-
tation to CD41 T cells, results from our studies have direct
implications on the pathogenesis of chronic disease states,
in which single activation of CD4 may take place, and
which are curiously characterized by CD41 T cell deple-
tion. Examples include SLE and HIV infection. In SLE a
significant increase in anti-CD4 antibodies has been noted,
which may correlate with the lymphopenia observed in
these patients (39). In the context of HIV infection, not
only is there an increase in circulating levels of anti-CD4
antibodies (40–42), but more importantly, in soluble gp120
(43), anti-gp120 antibodies (44, 45), and a large number of
defective HIV virions (46, 47), all of which can lead to a
chronic and significant degree of CD4 activation of unin-
fected CD41 T cells. As recently shown by our group,
CD41 T cells and not CD81 T cells from HIV infected pa-
tients are in a state of susceptibility to both FasL and TNF-
dependent apoptosis (6). This work further supports the
potential role of the in vivo activation of CD41 T cells by
the above-mentioned HIV-related factors. In fact, ongoing
studies demonstrate that rapid reductions of viral load using
highly active antiretroviral therapy directly correlates with
increases in peripheral CD41 T cells counts (46, 47), sug-
gesting that HIV-related factors may be directly involved in
conferring susceptibility to apoptosis in CD41 T cells. The
steady present enhanced state of susceptibility to apoptosis
mediated by FasL or TNF in these patients, together with
increased levels of these two ligands (14, 47–49) may par-
tially explain the significant degree of CD41 T cell deple-
tion observed in the context of HIV infection.
Results that derived from studying the mechanisms
whereby CD4 activation leads to a state of susceptibility to
FasL- or TNF-mediated apoptosis suggest that direct
mechanisms are involved. Previous studies indicated that
the production of cytokines such as TNF and IFN-g after
CD4 activation of PBMCs were sufficient to explain the
susceptibility to accessory cell–mediated apoptosis (7, 8,
11); which, as recently shown by our group, constitutively
express FasL (14). However, our data using purified, and
therefore CD41-monocyte depleted, CD41 T cells indi-
cate that protein synthesis is not required for the induction
of susceptibility. These results support our previous obser-
vation that suggest that increases in TNFR and Fas mem-
brane expression are not necessary for induction of suscep-
tibility to FasL- and TNF-mediated apoptosis. Based on
this, it is possible that CD4 directly induces a state of sus-
ceptibility of the activated CD41 T cells, and in addition,
the subsequent production of cytokines by the activated
CD41 T cell or CD41 monocytes may result in a second
wave of susceptibility to apoptosis that could affect not
only these activated CD41 T cells, but also other neighbor-
ing cells. The possibility that CD4 activation of down-
stream second messengers may directly influence molecules
that are involved in conferring susceptibility or resistance to
Fas or TNFRI-initiated apoptosis is of importance. It pro-718 CD4 Regulates Susceptibility to Fas and TNF
vides for the first time a valuable model with which to
study potential modifications of members of the Fas or
TNFRI signal pathways that may ensue after CD4 activa-
tion. Demonstrating that PKC is required for the induction
of susceptibility to FasL-mediated apoptosis of primary
CD41 T cells is a first important step, as it implies that
PKC-dependent phosphorylation is a necessary event in
rendering a resistant cell into one susceptible to FasL-medi-
ated, but interestingly not to TNFR-mediated, apoptosis.
Recent studies in transformed cells support our observa-
tion, as it has been shown that failure to activate PKC is as-
sociated with resistance to FasL-mediated apoptosis (50).
Because Fas and TNFRI have common intracellular mole-
cules, such as FADD or caspase-8 (FLICE; 51–55), the se-
lectively of PKC-dependent phosphorylation in the case of
Fas-initiated signal transduction implies that either Fas itself
or downstream molecules may be targeted by PKC.
In summary, our studies highlight the need to revisit the
role of CD4 as an important receptor that controls T cell
homeostasis. Identification of the molecular mechanism
controlling this process will be of significant value in un-
derstanding the regulation of the immune response and,
importantly, in determining its role in CD41 T cell deple-
tion in HIV-infected individuals.
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